Advertisement
Advertisement
EDIT
Editas Medicine, Inc. Common Stock
2.31
USDSponsored
-0.01
-0.65%
Mar 26, 15:58 UTC -4
Closed
After-Market
2.33
+0.02
+0.87%
EDIT Earnings Reports
Positive Surprise Ratio
EDIT beat 23 of 41 last estimates.
56%
Next Report
Date of Next Report
May 11, 2026
Estimate for Q1 26 (Revenue/ EPS)
$4.49M
/-$0.27
Implied change from Q4 25 (Revenue/ EPS)
-81.84%
/+350.00%
Implied change from Q1 25 (Revenue/ EPS)
-3.53%
/-70.65%
Editas Medicine, Inc. Common Stock earnings per share and revenue
On Mar 09, 2026, EDIT reported earnings of -0.06 USD per share (EPS) for Q4 25, beating the estimate of -0.26 USD, resulting in a 77.21% surprise. Revenue reached 24.74 million, compared to an expected 5.71 million, with a 333.53% difference. The market reacted with a +7.35% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 9 analysts forecast an EPS of -0.27 USD, with revenue projected to reach 4.49 million USD, implying an increase of 350.00% EPS, and decrease of -81.84% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
Acumen Pharmaceuticals, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.46
Actual
-$0.41
Surprise
+11.29%
Rani Therapeutics Holdings, Inc. Class A Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.07
Surprise
-2.94%
Spero Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.20
Actual
$0.53
Surprise
+359.80%
Alpha Cognition Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.30
Surprise
-8.93%
Cognition Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.02
Surprise
+76.47%
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
Quantum Biopharma Ltd. Class B Subordinate Voting Shares
Report Date
Mar 26, 2026 For Q4 25
Estimate
-Actual
-$0.71
Surprise
-
CollPlant Biotechnologies Ltd Ordinary Shares
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.67
Surprise
-245.72%
FAQ
What were Editas Medicine, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Editas Medicine, Inc. Common Stock reported EPS of -$0.06, beating estimates by 77.21%, and revenue of $24.74M, 333.53% above expectations.
How did the market react to Editas Medicine, Inc. Common Stock's Q4 2025 earnings?
The stock price moved up 7.35%, changed from $2.04 before the earnings release to $2.19 the day after.
When is Editas Medicine, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 11, 2026.
What are the forecasts for Editas Medicine, Inc. Common Stock's next earnings report?
Based on 9
analysts, Editas Medicine, Inc. Common Stock is expected to report EPS of -$0.27 and revenue of $4.49M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement